Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challenges
Issued Date
2023-09-01
Resource Type
ISSN
00062952
eISSN
18732968
Scopus ID
2-s2.0-85167969742
Pubmed ID
37567319
Journal Title
Biochemical Pharmacology
Volume
215
Rights Holder(s)
SCOPUS
Bibliographic Citation
Biochemical Pharmacology Vol.215 (2023)
Suggested Citation
Luangmonkong T., Parichatikanond W., Olinga P. Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challenges. Biochemical Pharmacology Vol.215 (2023). doi:10.1016/j.bcp.2023.115740 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/88823
Title
Targeting collagen homeostasis for the treatment of liver fibrosis: Opportunities and challenges
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Liver fibrosis is an excessive production, aberrant deposition, and deficit degradation of extracellular matrix (ECM). Patients with unresolved fibrosis ultimately undergo end-stage liver diseases. To date, the effective and safe strategy to cease fibrosis progression remains an unmet clinical need. Since collagens are the most abundant ECM protein which play an essential role in fibrogenesis, the suitable regulation of collagen homeostasis could be an effective strategy for the treatment of liver fibrosis. Therefore, this review provides a brief overview on the dysregulation of ECM homeostasis, focusing on collagens, in the pathogenesis of liver fibrosis. Most importantly, promising therapeutic mechanisms related to biosynthesis, deposition and extracellular interactions, and degradation of collagens, together with preclinical and clinical antifibrotic evidence of drugs affecting each target are orderly criticized. In addition, challenges for targeting collagen homeostasis in the treatment of liver fibrosis are discussed.